Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Colorectal Neoplasms 2Cardiotoxicity 2Breast Neoplasms 2Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peripheral Nervous System Diseases 1Leukemia 1Gastrointestinal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Cognitive Dysfunction 1

Interventions

Acupuncture Therapy 10Exercise 7Cryotherapy 6Paclitaxel 5Glutamine 5Surveys and Questionnaires 3Duloxetine Hydrochloride 3Dexamethasone 3Bortezomib 3Acetylcysteine 3Thioctic Acid 2Tablets 2Sodium Chloride 2Saline Solution 2Physical Therapy Modalities 2Low-Level Light Therapy 2Fish Oils 2Fatty Acids, Omega-3 2ziconotide 1sagopilone 1pembrolizumab 1nicotinamide-beta-riboside 1nabilone 1glutamic acid diethyl ester 1enfortumab vedotin 1allantoicase 1Yoga 1XELOX 1Vitamin D 1Vitamin B Complex 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Peripheral Nervous System Diseases × Silymarin × Clear all
NCT05595109 2022-10-26

Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients

Tanta University

Phase 2/3 Unknown
56 enrolled
Breast

Breast Neoplasms, Peripheral Nervous System Diseases, Cognitive Dysfunction, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡